Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Silence Therapeutics plc is a biotechnology company specializing in RNA interference (RNAi) therapeutics, focusing on developing siRNA molecules to target diseases with significant unmet medical needs. Its key products include divesiran for polycythemia vera and zerlasiran for cardiovascular disease linked to elevated lipoprotein(a). With a robust pipeline and proprietary mRNAi GOLD platform, Silence aims to address critical health challenges while exploring partnerships for further development and commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.